Alps Advisors Inc. boosted its stake in Loxo Oncology, Inc. (NASDAQ:LOXO) by 24.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 29,401 shares of the biopharmaceutical company’s stock after buying an additional 5,800 shares during the period. Alps Advisors Inc. owned 0.10% of Loxo Oncology worth $2,708,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Candriam Luxembourg S.C.A. lifted its holdings in Loxo Oncology by 38.4% in the third quarter. Candriam Luxembourg S.C.A. now owns 102,400 shares of the biopharmaceutical company’s stock worth $9,433,000 after buying an additional 28,400 shares during the period. Smith Asset Management Group LP purchased a new stake in Loxo Oncology in the third quarter worth about $408,000. State Board of Administration of Florida Retirement System lifted its holdings in Loxo Oncology by 16.7% in the third quarter. State Board of Administration of Florida Retirement System now owns 9,760 shares of the biopharmaceutical company’s stock worth $899,000 after buying an additional 1,400 shares during the period. Parametrica Management Ltd purchased a new stake in Loxo Oncology in the third quarter worth about $500,000. Finally, Pictet Asset Management Ltd. lifted its holdings in Loxo Oncology by 14.5% in the third quarter. Pictet Asset Management Ltd. now owns 241,402 shares of the biopharmaceutical company’s stock worth $22,238,000 after buying an additional 30,636 shares during the period.

LOXO has been the subject of several research analyst reports. Morgan Stanley restated an “overweight” rating and issued a $103.00 price objective (up from $95.00) on shares of Loxo Oncology in a report on Friday, October 6th. Ifs Securities reaffirmed an “outperform” rating on shares of Loxo Oncology in a research note on Tuesday, August 8th. Citigroup Inc. reaffirmed a “buy” rating and set a $112.00 target price (up previously from $86.00) on shares of Loxo Oncology in a research note on Friday, October 20th. Stifel Nicolaus reaffirmed a “buy” rating and set a $71.00 target price on shares of Loxo Oncology in a research note on Thursday, August 3rd. Finally, BTIG Research reaffirmed a “buy” rating and set a $102.00 target price (up previously from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Loxo Oncology presently has an average rating of “Buy” and an average price target of $80.02.

In related news, insider Naarden Jacob Van sold 1,541 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $73.73, for a total transaction of $113,617.93. Following the completion of the sale, the insider now owns 1,541 shares of the company’s stock, valued at $113,617.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Avi Z. Naider sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $90.00, for a total transaction of $450,000.00. Following the sale, the director now directly owns 154,118 shares of the company’s stock, valued at approximately $13,870,620. The disclosure for this sale can be found here. Insiders have sold 105,637 shares of company stock valued at $8,670,337 in the last three months. 44.40% of the stock is owned by insiders.

Shares of Loxo Oncology, Inc. (LOXO) traded up $1.05 on Friday, hitting $81.18. 296,300 shares of the company traded hands, compared to its average volume of 371,794. Loxo Oncology, Inc. has a 12 month low of $23.86 and a 12 month high of $95.92.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/loxo-oncology-inc-loxo-shares-bought-by-alps-advisors-inc/1698237.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.